和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

未开盘 07-30 16:08:22

11.690

-0.570

-4.65%

最高12.210	最低11.500	成交量279.41万
今开12.100	昨收12.260	日振幅5.79%
总市值101.47亿	流通市值101.47亿	总股本8.68亿
成交额3,290万	换手率0.32%	流通股本8.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":11.69,"timestamp":1785398902003,"preClose":12.26,"halted":0,"volume":2794109,"delay":0,"changeRate":-0.04649265905383363,"floatShares":868000000,"shares":868000000,"eps":0.862792467037406,"marketStatus":"未开盘","change":-0.57,"latestTime":"07-30 16:08:22","open":12.1,"high":12.21,"low":11.5,"amount":32901753,"amplitude":0.057912,"askPrice":11.7,"askSize":6000,"bidPrice":11.69,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.8627846234695239,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785461400000},"marketStatusCode":0,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":12.26,"openAndCloseTimeList":[[1785375000000,1785384000000],[1785387600000,1785398400000]],"volumeRatio":1.0386357423127548,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142","defaultTab":"news","newsList":[{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0359202008.SGD","IE00B5MMRT66.SGD","06185","BK1141","LU0588546209.SGD","601211","LU1719994722.HKD","02611","02142","KURE","LU2476274308.USD","06160","02616","161027","IE00B543WZ88.USD","LU0052750758.USD","LU0181495838.USD","BK1583","LU0417516738.SGD","LU0348784397.USD","BK1588","09926","LU0634319403.HKD","IE00B0JY6N72.USD","SG9999002463.SGD","09688","LU2242644610.SGD","LU1720050803.USD","BK1147","09995","HK0000165453.HKD","LU0307460666.USD","LU0561508036.HKD","01093","01877","KCE","LU0051755006.USD","02269","LU1251922891.USD","LU1328277881.USD","01177","BK1564","01801","BK1610","LU0067412154.USD","LU1008478684.HKD","LU0979878070.USD","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654016344","title":"和铂医药与国药集团战略合作 拓创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2654016344","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654016344?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:39","pubTimestamp":1785145184,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02142","BK1161","BK1574","BK1583","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185769222","title":"和铂医药-B（02142）携手国药集团组建创新联合体　共推肿瘤及免疫炎症生物药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1185769222","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185769222?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:05","pubTimestamp":1785143146,"startTime":"0","endTime":"0","summary":"和铂医药-B7月27日发布自愿公告称，公司已与中国医药集团有限公司签署战略合作协议，双方将成立“国药集团—和铂医药创新联合体”，围绕创新型生物药全生命周期开展合作，重点聚焦肿瘤及免疫炎症等疾病领域。根据协议，和铂医药-B将依托其全人源抗体技术平台Harbour Mice及人工智能赋能的药物研发能力，与国药集团共同进行候选抗体分子的发现与优化，涵盖靶点确认、先导抗体发现及优化、抗体构型设计和抗体工程等环节。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654015307","title":"和铂医药-B(02142)与国药集团签署战略合作协议 以建立国药集团-和铂医药创新联合体","url":"https://stock-news.laohu8.com/highlight/detail?id=2654015307","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654015307?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:02","pubTimestamp":1785142967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，本公司已与中国医药集团有限公司签署战略合作协议，以建立国药集团-和铂医药创新联合体，并就创新型生物药的研发领域开展合作，战略重点覆盖肿瘤及免疫炎症等疾病领域。根据战略合作，本集团与国药集团将围绕创新型生物药的全生命周期开展研发合作，战略重点覆盖肿瘤及免疫炎症等疾病领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198876424","title":"和铂医药-B与中国医药集团达成生物药研发战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1198876424","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198876424?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:02","pubTimestamp":1785142960,"startTime":"0","endTime":"0","summary":"和铂医药-B（HBM Holdings-B）正式宣布，已与中国医药集团有限公司（国药集团）签署战略合作协议，双方将聚焦生物药研发领域展开深度协作。此次合作标志着这家专注于创新疗法的生物技术公司，在拓展国内战略伙伴关系方面迈出了关键一步。根据协议，双方将整合各自在生物药研发、技术平台及产业化资源上的优势，共同推进包括新型抗体药物在内的前沿项目。这一合作不仅有望加速候选药物的临床转化进程，也为和铂医药在生物药领域的长远布局注入了新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653705587","title":"港股异动 | 和铂医药-B(02142.HK)盈喜后涨超4% 预计中期溢利约6200万美元至约6700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653705587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653705587?lang=zh_cn&edition=full","pubTime":"2026-07-24 09:33","pubTimestamp":1784856788,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02142","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112421585","title":"和铂医药-B披露正面盈利预告：上半年收入最高1.25亿美元，预计实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=1112421585","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112421585?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:06","pubTimestamp":1784851570,"startTime":"0","endTime":"0","summary":"2026年7月24日，和铂医药-B发布正面盈利预告称，根据截至2026年6月30日止六个月的初步未审计管理账目，预计期内收入介乎约1.2亿美元至1.25亿美元，较2025年同期1.01亿美元显著增长。公司同时预期，上半年溢利将在约62百万美元至67百万美元之间；经调整溢利总额预计为70百万美元至75百万美元。和铂医药-B表示，以上财务数据尚未经过董事会旗下审核委员会或公司核数师的审阅，最终业绩将于2026年8月底发布的中期业绩公告中披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772889","title":"和铂医药-B(02142)发盈喜 预计中期溢利约6200万美元至约6700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772889","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653772889?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:05","pubTimestamp":1784851541,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，预期截至2026年6月30日止六个月的收入介乎约1.2亿美元至约1.25亿美元，而截至2025年6月30日止六个月的收入则为约1.01亿美元。预期截至2026年6月30日止六个月的溢利介乎约6200万美元至约6700万美元。预期经调整溢利总额介乎7000万美元至7500万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772662","title":"和铂医药发布2026年中期盈利预喜：实现连续七个半年度盈利，平台型药企优势助力业绩可持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772662","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653772662?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:02","pubTimestamp":1784851320,"startTime":"0","endTime":"0","summary":"中国上海，美国马萨诸塞州剑桥和荷兰鹿特丹2026年7月24日 /美通社/ -- 和铂医药，一家专注于免疫性疾病、肿瘤及其他领域创新抗体疗法发现及开发的全球生物医药公司，今日发布截至2026年6月30日的中期业绩盈利预喜。和铂医药实现连续七个半年度盈利，标志着公司正式跨入\"常态化盈利\"阶段，进一步验证了平台型制药集团商业模式的可持续性和可复制性。报告期内，公司多项重磅合作贡献显著收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5010897_ZH10897_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5010897_ZH10897_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","BK1161","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130107379","title":"和铂医药与维也纳医科大学达成研究合作，共同推进感染性疾病全人源抗体开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1130107379","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130107379?lang=zh_cn&edition=full","pubTime":"2026-07-23 08:56","pubTimestamp":1784768173,"startTime":"0","endTime":"0","summary":"和铂医药宣布，已与维也纳医科大学建立研究合作关系，双方将携手推进针对感染性疾病的全人源抗体开发项目。此项合作旨在利用和铂医药的专有技术平台与维也纳医科大学的学术研究专长，加速创新疗法的发现与转化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652036024","title":"港股异动 | 和铂医药-B(02142.HK)盘中跌超10% 辉瑞宣布终止和铂ADC药物SGN-MesoC2全部研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652036024","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652036024?lang=zh_cn&edition=full","pubTime":"2026-07-17 15:53","pubTimestamp":1784274820,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02142","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145145","title":"和铂医药-B(02142)：HBM7575用于治疗哮喘的新药临床试验申请获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145145","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651145145?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:02","pubTimestamp":1784109738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)公布，靶向胸腺基质淋巴细胞生成素(TSLP)及一个未公开靶点的长效双特异性抗体HBM7575(亦称SKB575)的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准，用于治疗哮喘。该款双特异性抗体由公司与四川科伦博泰生物医药股份有限公司(科伦博泰) (06990)合作研发。此前，HBM7575/SKB575用于治疗特应性皮炎的I期临床研究已顺利完成首例受试者给药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02142","IBBQ","BK1161","BMED","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651991128","title":"【券商聚焦】中信证券：新基药目录有望加速创新药基层落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651991128","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651991128?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:57","pubTimestamp":1783990650,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，《2026年版国家基本药物目录》于7月9日正式发布，将于9月1日起实施。该机构认为，本次新版基药目录新增药物均已属于医保药品，随着基药与医保的深度协同联动，有望极大加速创新药的基层落地，医保控费与创新回报形成良性循环。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985769","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0327786744.USD","LU1997244956.HKD","BK1610","BK1161","06160","06978","LU1152091168.USD","BK1500","LU1960683339.HKD","HK0000165453.HKD","KURE","LU0588546209.SGD","LU0359201612.USD","KCE","06185","600030","IE0008368742.USD","LU0572944931.SGD","02616","IE00BPRC5H50.USD","01877","LU0823426480.USD","LU2328871848.SGD","LU0417516902.SGD","01801","LU1242518931.SGD","LU0979878070.USD","01177","LU1328277881.USD","09688","06030","LU1226287792.SGD","LU0051755006.USD","LU2476274720.SGD","LU0314109678.HKD","LU2039709279.SGD","LU0043850808.USD","09926","02142","LU1961090484.USD","SG9999002463.SGD","159992","IBBQ","LU2488822045.USD","02269","MEDX","LU1226288253.USD","09995","LU0405327494.USD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU0348825331.USD","LU2488822045.USD","BD","IE00B0JY6N72.USD","06160","06185","LU0359202008.SGD","02616","01177","159992","09926","LU2097828631.EUR","LU1226288170.HKD","02142","IE0008369823.USD","LU0456846285.SGD","LU0067412154.USD","MEDX","LU1993786604.SGD","06978","IE00B5MMRT66.SGD","LU2242644610.SGD","601066","LU1807302812.USD","01877","KURE","01093","LU1813983027.USD","LU0455707207.USD","LU2097828474.EUR","LU0516422366.SGD","LU0501845795.SGD","LU1969619763.USD","LU0348784397.USD","09688","LU0359201612.USD","BK1588","BK1161","KCE","LU1960683339.HKD","01801","BK1515","LU0348735423.USD","LU1688375341.USD","LU1961090484.USD","02269","IE0008368742.USD","LU0051755006.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112036125","title":"和铂医药-B更新2026年6月股份变动月报表，股本小幅增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1112036125","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112036125?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:46","pubTimestamp":1783414002,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年7月7日公布了截至2026年6月30日的股份变动月报表。报告期内，公司法定/注册股本与上月保持一致，注册股本总额为USD 500,000，未见变动。本月末，公司已发行股份总数小幅增长，公众持股量符合香港联交所相关要求。公司在公告中声明已遵守香港联交所《上市规则》及相关法律规定，所有有关本期股份发行及转让事项均已获董事会授权批准。公告由执行董事王劲松签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634520","title":"【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634520","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634520?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:36","pubTimestamp":1783038993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研究指，2026年6月29日，国家医保局公示通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单及相关信息。叠加今年首次引入的“预申报”机制，本次结果充分体现了医保目录调整对创新药的持续倾斜，看好相关创新药及制药企业的医保准入与商保增量空间。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601066","LU2778985437.USD","159992","09688","01877","LU1969619763.USD","LU2097828805.USD","LU0072913022.USD","LU0856984785.SGD","LU0502904849.HKD","LU0315179316.USD","LU0067412154.USD","LU0516422366.SGD","HK0000165453.HKD","02142","BK1589","LU1961090484.USD","LU0501845795.SGD","LU0417516738.SGD","06185","LU2097828631.EUR","LU0043850808.USD","LU0348766576.USD","09926","01477","01093","02616","IE0008369823.USD","LU1226287875.USD","LU2488822045.USD","06160","LU2039709279.SGD","02269","LU3063872942.SGD","09995","IE00B031HY20.USD","LU2476274308.USD","LU1242518931.SGD","SG9999004220.SGD","LU2476274720.SGD","01177","LU0417516902.SGD","IE00B5MMRT66.SGD","LU2097828714.EUR","06978","LU1688375341.USD","LU0979878070.USD","01801","LU1226287792.SGD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146509604","title":"和铂医药与龙沙达成战略合作 共同开发中枢神经系统疾病领域顶尖单域抗体血脑屏障穿透技术","url":"https://stock-news.laohu8.com/highlight/detail?id=1146509604","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146509604?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:07","pubTimestamp":1782950842,"startTime":"0","endTime":"0","summary":"和铂医药与龙沙集团宣布建立战略合作关系，双方将携手开发用于治疗中枢神经系统疾病的、基于单域抗体的顶尖血脑屏障穿透技术。此项合作旨在结合双方在生物技术研发与生产领域的专长，共同推进创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06106","03310","02672","03355","06938","02335","01672","09637","01609","02632","01021","02723","00412","01133","03625","07688","01879","03388","01191","01956","06636","01236","01511","01392","03887","06872","01286","02553","02726","02142","01651","BK4585","03661","00376","02272","01866","09630","06656","06658","01779","02696","02670","06675","00100","07630","00863","01081","03277","00600","00068","02729","02616","00340","07666","01440","02526","BK4588"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2646840322","title":"【券商聚焦】中信证券：中国创新药BD交易金额超预期增长 即将进入密集数据催化期","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840322","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646840322?lang=zh_cn&edition=full","pubTime":"2026-06-25 09:03","pubTimestamp":1782349398,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研报指，2026年以来，中国创新药BD交易金额超预期增长，产业全球竞争力进一步提升；国内市场快速放量，从2025年报来看，头部创新药企业在新产品驱动下，创新药收入快速增长，Biopharma陆续进入盈利拐点。研报认为创新药产业全球价值凸显，接下来将进入密集数据催化期。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984448","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","09995","LU1064130708.USD","06185","BK1610","IE00BZ08YT58.USD","LU1997245094.SGD","LU0501845795.SGD","LU2097828474.EUR","09688","600030","LU0405327148.USD","BK0028","IE00B0JY6N72.USD","01801","IE00B5MMRT66.SGD","LU1328277881.USD","09926","LU1794554557.SGD","LU2289578879.USD","02616","LU2039709279.SGD","LU1813983027.USD","SG9999004220.SGD","LU1226288253.USD","LU0327786744.USD","06160","SG9999002562.SGD","01093","BK1574","159992","LU0540923850.HKD","IE0008368742.USD","01877","LU0181495838.USD","06030","LU0348767384.USD","BD","LU1242518857.USD","01177","LU2328871848.SGD","06978","BK0196","IE00B031HY20.USD","LU0359202008.SGD","LU0856984785.SGD","LU0823426480.USD","LU1960683339.HKD","02269","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643223425","title":"和铂医药-B(02142)诉安进专利侵权胜诉获赔约2020.37万美元 最高可追偿三倍赔偿金","url":"https://stock-news.laohu8.com/highlight/detail?id=2643223425","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643223425?lang=zh_cn&edition=full","pubTime":"2026-06-15 08:32","pubTimestamp":1781483572,"startTime":"0","endTime":"0","summary":"经过2026年6月8日开始的陪审团庭审后，陪审团认定：安进侵犯了Grosveld专利，该侵权行为属于故意侵权， Grosveld专利有效，及 Harbour Antibodies有权获得约2020.37万美元的损害赔偿——即公司请求的全额赔偿。故意侵权的认定使Harbour Antibodies有权请求法院提高损害赔偿金额，可能包括最高三倍的损害赔偿。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1023059063.AUD","LU2112291526.USD","IE00B2B36J28.USD","BK4585","IE0009355771.USD","BK1161","BK4139","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4534","LU0109394709.USD","LU1983299246.USD","02142","BK4533","IE00BJJMRZ35.SGD","LU0058720904.USD","LU2242646821.SGD","BK1583","SG9999001440.SGD","BK1574","LU0289739699.SGD","LU1057294990.SGD","BK4566","IE00BJT1NW94.SGD","LU0889565916.HKD","BK4581","LU1571399168.USD","IE00B4R5TH58.HKD","AMGN","LU2242652126.USD","LU1061106388.HKD","LU0868494617.USD","BK4588","BK4599","LU0122379950.USD","LU2089984988.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0534},{"period":"1month","weight":0.1197},{"period":"3month","weight":-0.1015},{"period":"6month","weight":-0.0176},{"period":"1year","weight":0.135},{"period":"ytd","weight":-0.0387}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":0.1301},{"period":"3month","weight":0.0032},{"period":"6month","weight":-0.0558},{"period":"1year","weight":0.0271},{"period":"ytd","weight":0.0089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品主要包括巴托利单抗（HBM9161）、HBM9378、HBM7020、TCE Program、普鲁苏拜单抗（HBM4003）以及HBM7022等。该公司产品主要用于治疗全身型重症肌无力（gMG）、慢性阻塞性肺病（COPD）、哮喘、自身免疫疾病、黑色素瘤、结直肠癌以及实体瘤等。该公司通过专有抗体技术平台“Harbour Mice”、“HBICE”、“HBICA”及单克隆B细胞筛选平台提供下一代抗体以及生物解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.016802},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.072876},{"month":7,"riseRate":0.5,"avgChangeRate":0.045253},{"month":8,"riseRate":0.2,"avgChangeRate":0.005624},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065735},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}